BMO Capital Markets set a $73.00 target price on Eli Lilly and Company (NYSE:LLY) in a report issued on Monday, October 16th. The firm currently has a sell rating on the stock.
A number of other brokerages also recently weighed in on LLY. UBS AG downgraded shares of Eli Lilly and to a hold rating and set a $85.00 price objective for the company. in a research report on Wednesday, July 26th. Jefferies Group LLC reaffirmed a buy rating and set a $93.00 price objective on shares of Eli Lilly and in a research report on Thursday, June 22nd. Morgan Stanley set a $86.00 price objective on shares of Eli Lilly and and gave the company a hold rating in a research report on Friday, October 6th. Piper Jaffray Companies reissued a buy rating and set a $105.00 target price on shares of Eli Lilly and in a research note on Friday, October 13th. Finally, Berenberg Bank reissued a buy rating and set a $98.00 target price on shares of Eli Lilly and in a research note on Friday, August 4th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have assigned a buy rating to the company. Eli Lilly and presently has an average rating of Hold and a consensus target price of $89.76.
Eli Lilly and (NYSE:LLY) traded down 0.36% on Monday, reaching $83.86. The company’s stock had a trading volume of 2,892,945 shares. The company has a 50 day moving average of $84.74 and a 200 day moving average of $82.27. Eli Lilly and has a 52 week low of $64.18 and a 52 week high of $89.09. The firm has a market capitalization of $88.47 billion, a price-to-earnings ratio of 36.29 and a beta of 0.34.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, beating analysts’ consensus estimates of $1.03 by $0.02. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.72%. The business had revenue of $5.66 billion during the quarter, compared to the consensus estimate of $5.52 billion. During the same quarter in the prior year, the firm earned $0.88 EPS. The company’s revenue for the quarter was up 9.0% compared to the same quarter last year. On average, analysts forecast that Eli Lilly and will post $4.20 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Eli Lilly and Company (NYSE:LLY) Given a $73.00 Price Target by BMO Capital Markets Analysts” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2017/10/28/bmo-capital-markets-analysts-give-eli-lilly-and-company-lly-a-73-00-price-target.html.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Wednesday, November 15th will be issued a dividend of $0.52 per share. The ex-dividend date of this dividend is Tuesday, November 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.48%. Eli Lilly and’s dividend payout ratio is currently 98.58%.
In other news, major shareholder Lilly Endowment Inc sold 180,000 shares of the business’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $81.06, for a total transaction of $14,590,800.00. Following the sale, the insider now owns 123,865,804 shares in the company, valued at $10,040,562,072.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 990,000 shares of company stock worth $82,949,650 in the last 90 days. 0.20% of the stock is owned by company insiders.
Institutional investors have recently added to or reduced their stakes in the business. Pathstone Family Office LLC increased its stake in Eli Lilly and by 100.0% in the 2nd quarter. Pathstone Family Office LLC now owns 58 shares of the company’s stock valued at $4,774,000 after buying an additional 29 shares during the period. Vantage Financial Partners Ltd. Inc. acquired a new position in Eli Lilly and in the 2nd quarter valued at approximately $494,000. Acrospire Investment Management LLC increased its stake in Eli Lilly and by 16.7% in the 2nd quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock valued at $115,000 after buying an additional 200 shares during the period. MPS Loria Financial Planners LLC acquired a new position in Eli Lilly and in the 2nd quarter valued at approximately $128,000. Finally, San Francisco Sentry Investment Group CA acquired a new position in Eli Lilly and in the 2nd quarter valued at approximately $129,000. Hedge funds and other institutional investors own 75.61% of the company’s stock.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.